Protagenic Therapeutics Stock Forward View - Simple Regression
| PTIX Stock | USD 0.59 0.10 20.41% |
Forecasting Protagenic Therapeutics stock price is inherently uncertain, but structured approaches to analyzing market sentiment can improve the odds. This module tracks the noise around Protagenic Therapeutics to identify periods where price and perception diverge.
Using the latest data, the 14-period RSI for Protagenic Therapeutics is 0, signaling extreme oversold conditions. Readings below 20 are commonly associated with potential stabilization zones.Momentum
Sell Peaked
Oversold | Overbought |
Wall Street Target Price 4 |
This section relates Protagenic Therapeutics headline activity to recent price behavior and peer context.
The Simple Regression forecasted value of Protagenic Therapeutics on the next trading day is expected to be 0.17 with a mean absolute deviation of 0.21 and the sum of the absolute errors of 12.58.Protagenic Therapeutics after-hype prediction price | $ 0.6 |
Sentiment indicators are one input among forecasting models, technical signals, analyst estimates, earnings data, and momentum measures.
Protagenic | Build portfolio with Protagenic Stock |
Protagenic Therapeutics Additional Predictive Modules
Predictive models for Protagenic Therapeutics combine technical indicators with statistical methods to estimate probable price trajectories. Predictive models for Protagenic work best when confirmed by real-time indicator readings.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Regression Price Forecast For the 18th of March 2026
Given 90 days horizon, the Simple Regression forecasted value of Protagenic Therapeutics on the next trading day is expected to be 0.17 with a mean absolute deviation of 0.21 , mean absolute percentage error of 0.06 , and the sum of the absolute errors of 12.58 .Please note that although there have been many attempts to predict Protagenic Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Protagenic Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Protagenic Therapeutics | Protagenic Therapeutics Price Prediction | Research Analysis |
Forecasted Value
For the next trading day, Macroaxis evaluates Protagenic Therapeutics' predictive range by looking for statistically meaningful downside and upside boundaries. At the moment, the model places downside around 0.01 and upside around 13.49 for the forecasting period.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Protagenic Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Protagenic Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 115.227 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.2062 |
| MAPE | Mean absolute percentage error | 0.3241 |
| SAE | Sum of the absolute errors | 12.5803 |
The mean reversion principle applied to Protagenic Therapeutics' suggests that neither prolonged outperformance nor underperformance is permanent. Investors exploit this by positioning against extremes in price relative to fundamental value.
After-Hype Price Density Analysis
Probability distributions applied to Protagenic Therapeutics price forecasting provide a more honest representation of uncertainty than single point estimates. The shape of Protagenic Therapeutics' distribution - whether it is symmetric, skewed, or fat-tailed - carries important information for risk.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
News-driven price analysis for Protagenic Therapeutics quantifies the historical relationship between headline events and Protagenic Therapeutics' short-term price response. Protagenic Therapeutics' after-hype downside and upside margins for the prediction period are 0.03 and 13.92, respectively. The strength of this signal depends on the consistency of Protagenic Therapeutics's past reactions to comparable news categories.
Current Value
The after-hype framework applied to Protagenic Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. The objective is to separate event-driven enthusiasm from a more stable price path once the market absorbs the catalyst.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Protagenic Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protagenic Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Protagenic Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.56 | 13.32 | 0.01 | 0.01 | 4 Events | 7 Events | In 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.59 | 0.60 | 1.69 |
|
Hype Timeline
Protagenic Therapeutics is at this time traded for 0.59. The company has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.01. Protagenic is forecasted to increase in value after the next headline, with the price projected to jump to 0.6 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 1.69%, whereas the daily expected return is at this time at -0.56%. The volatility of related hype on Protagenic Therapeutics is about 101679.39%, with the expected price after the next announcement by competition of 0.58. Net Loss for the year was -5.16 M with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next forecasted press release will be in 4 days. Use Historical Fundamental Analysis of Protagenic Therapeutics to cross-verify projections for Protagenic Therapeutics. The historical view provides additional context.Related Hype Analysis
When a direct competitor of Protagenic Therapeutics experiences a significant news event, the market often re-rates Protagenic Therapeutics' shares in sympathy or in contrast, depending on whether the news affects the sector broadly or competitively.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SLRX | Salarius Pharmaceuticals | -0.02 | 6 per month | 0.00 | -0.18 | 16.00 | -16.92 | 61.05 | |
| LIPO | Lipella Pharmaceuticals Common | 0.11 | 26 per month | 0.00 | 0.0004 | 18.75 | -21.74 | 94.73 | |
| ARTL | Artelo Biosciences | 0.42 | 6 per month | 0.00 | -0.05 | 9.09 | -7.64 | 29.57 | |
| INDP | Indaptus Therapeutics | -0.14 | 7 per month | 0.00 | -0.04 | 11.52 | -8.64 | 51.64 | |
| SLXN | Biomotion Sciences Ordinary | -0.15 | 4 per month | 0.00 | -0.13 | 10.98 | -9.17 | 29.74 | |
| REVB | Revelation Biosciences | 0.09 | 9 per month | 0.00 | -0.29 | 5.56 | -10.16 | 34.09 | |
| CARM | Carisma Therapeutics | -0.001 | 2 per month | 0.00 | -0.01 | 14.29 | -13.04 | 56.42 | |
| SPRC | Scisparc | -0.40 | 9 per month | 0.00 | -0.25 | 11.44 | -12.35 | 48.25 | |
| GTBP | GT Biopharma | 0.02 | 8 per month | 0.00 | -0.07 | 8.33 | -10.64 | 37.01 | |
| PBM | Psyence Biomedical Ltd | -0.06 | 9 per month | 0.00 | -0.20 | 9.96 | -12.68 | 48.52 |
Other Forecasting Options for Protagenic Therapeutics
Regardless of investment experience, understanding Protagenic Therapeutics' price movement is essential for anyone considering a position in Protagenic. Price charts for Protagenic Stock are often filled with noise that can lead to poor investment choices if not properly filtered.Protagenic Therapeutics Related Equities
The following equities are related to Protagenic Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Protagenic Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Protagenic Therapeutics Market Strength Events
Market strength indicators for Protagenic Therapeutics give investors insight into the stock's responsiveness to broader market forces. Tracking these indicators helps investors make informed timing decisions and identify periods where trading Protagenic Therapeutics is likely to be most rewarding.
| Accumulation Distribution | 0.17 | |||
| Daily Balance Of Power | 1.0 | |||
| Rate Of Daily Change | 1.2 | |||
| Day Median Price | 0.54 | |||
| Day Typical Price | 0.56 | |||
| Market Facilitation Index | 0.1 | |||
| Price Action Indicator | 0.1 | |||
| Period Momentum Indicator | 0.1 |
Protagenic Therapeutics Risk Indicators
A thorough review of Protagenic Therapeutics' risk indicators is an important first step in forecasting its price and managing investment exposure. This analysis helps investors determine the appropriate level of risk to accept when holding Protagenic Therapeutics'.
| Mean Deviation | 8.67 | |||
| Standard Deviation | 12.22 | |||
| Variance | 149.36 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Protagenic Therapeutics
Coverage intensity for Protagenic Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. A disciplined read of coverage helps investors separate durable relevance from temporary noise.
Contributor Headline
Latest Perspective From Macroaxis
Protagenic Therapeutics Short Properties
A short-interest review of Protagenic Therapeutics helps investors understand whether skepticism in the market is becoming more influential. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 1.9 M | |
| Cash And Short Term Investments | 2.2 M |
More Resources for Protagenic Stock Analysis
A comprehensive view of Protagenic Therapeutics starts with financial statements and ratio context. Ratio analysis helps investors evaluate Protagenic Therapeutics Stock operating efficiency and financial trajectory. Highlighted below are reports that provide context for Protagenic Therapeutics Stock:Use Historical Fundamental Analysis of Protagenic Therapeutics to cross-verify projections for Protagenic Therapeutics. The historical view provides additional context. New to investing in Protagenic Stock? Start with our How to Invest in Protagenic Stock guide for a step-by-step overview.With Protagenic Therapeutics showing P/E 9.43 and ROE -5.13%, investors get more value when this analysis is combined with the diversification and construction tools below. That discounted valuation invites deeper analysis through the value and risk tools below. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Investors evaluate Protagenic Therapeutics using market value and book value, each describing different facets of the business. Protagenic Therapeutics' market capitalization is 944.67 K. The 3.35 P/B ratio shows Protagenic Therapeutics carries a substantial premium over its balance-sheet equity. Enterprise value stands at 2.22 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Protagenic Therapeutics' value from its trading price, which are computed with different methods. For Protagenic Therapeutics, key inputs include a P/E ratio of 9.43, a P/B ratio of 3.35, and ROE of -5.13%. In practice, Protagenic Therapeutics price is set by the continuous auction process on its listing exchange.